Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Dual roles for the TSPYL family in mediating serotonin transport and the metabolism of selective serotonin reuptake inhibitors in MDD patients.

Qin S, Eugene AR, Liu D, Zhang L, Neavin D, Biernacka JM, Yu J, Weinshilboum RM, Wang L.

Clin Pharmacol Ther. 2019 Oct 19. doi: 10.1002/cpt.1692. [Epub ahead of print]

PMID:
31628858
2.

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.

Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, Ahmed AT, Louie G, Frye MA, Weinshilboum RM, Krishnan RR, Rush AJ, Mayberg HS, Craighead WE, Kaddurah-Daouk R.

Front Neurosci. 2019 Sep 12;13:926. doi: 10.3389/fnins.2019.00926. eCollection 2019.

3.

Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?

Athreya AP, Iyer R, Wang L, Weinshilboum RM, Bobo WV.

Pharmacogenomics. 2019 Sep;20(14):983-988. doi: 10.2217/pgs-2019-0119. No abstract available.

4.

Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol).

Bielinski SJ, St Sauver JL, Olson JE, Larson NB, Black JL, Scherer SE, Bernard ME, Boerwinkle E, Borah BJ, Caraballo PJ, Curry TB, Doddapaneni H, Formea CM, Freimuth RR, Gibbs RA, Giri J, Hathcock MA, Hu J, Jacobson DJ, Jones LA, Kalla S, Koep TH, Korchina V, Kovar CL, Lee S, Liu H, Matey ET, McGree ME, McAllister TM, Moyer AM, Muzny DM, Nicholson WT, Oyen LJ, Qin X, Raj R, Roger VL, Rohrer Vitek CR, Ross JL, Sharp RR, Takahashi PY, Venner E, Walker K, Wang L, Wang Q, Wright JA, Wu TJ, Wang L, Weinshilboum RM.

Int J Epidemiol. 2019 Aug 4. pii: dyz123. doi: 10.1093/ije/dyz123. [Epub ahead of print] No abstract available.

PMID:
31378813
5.

Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.

Ruddy KJ, Schaid DJ, Partridge AH, Larson NB, Batzler A, Häberle L, Dittrich R, Widschwendter P, Fink V, Bauer E, Schwitulla J, Rübner M, Ekici AB, Aivazova-Fuchs V, Stewart EA, Beckmann MW, Ginsburg E, Wang L, Weinshilboum RM, Couch FJ, Janni W, Rack B, Vachon C, Fasching PA.

Fertil Steril. 2019 Oct;112(4):731-739.e1. doi: 10.1016/j.fertnstert.2019.05.018. Epub 2019 Jul 29.

PMID:
31371054
6.

Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand-Dependent Gene Expression.

Neavin DR, Lee JH, Liu D, Ye Z, Li H, Wang L, Ordog T, Weinshilboum RM.

Drug Metab Dispos. 2019 Sep;47(9):983-994. doi: 10.1124/dmd.119.087312. Epub 2019 Jul 10.

PMID:
31292129
7.

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.

Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Zhu H, Mahmoudiandehkordi S, Neavin D, Louie G, Dunlop BW, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk R.

Transl Psychiatry. 2019 Jul 4;9(1):173. doi: 10.1038/s41398-019-0507-5.

8.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.

Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

9.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2019 Oct;29(8):183-191. doi: 10.1097/FPC.0000000000000382.

PMID:
31211741
10.

Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities.

Ho MF, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Aug;106(2):281-283. doi: 10.1002/cpt.1452. Epub 2019 May 13. No abstract available.

11.

Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.

Athreya AP, Neavin D, Carrillo-Roa T, Skime M, Biernacka J, Frye MA, Rush AJ, Wang L, Binder EB, Iyer RK, Weinshilboum RM, Bobo WV.

Clin Pharmacol Ther. 2019 Oct;106(4):855-865. doi: 10.1002/cpt.1482. Epub 2019 Jun 29.

12.

Clopidogrel Pharmacogenetics.

Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME.

Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811.

PMID:
30998396
13.

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Cairns J, Ingle JN, Kalari KR, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Wang L.

Breast Cancer Res. 2019 Apr 3;21(1):47. doi: 10.1186/s13058-019-1130-3.

14.

4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM, Shen K, Wang L.

Breast Cancer Res Treat. 2019 Jun;175(3):567-578. doi: 10.1007/s10549-019-05194-z. Epub 2019 Apr 1.

PMID:
30937657
15.

Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM.

Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11.

PMID:
30745309
16.

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.

Kalari KR, Sinnwell JP, Thompson KJ, Tang X, Carlson EE, Yu J, Vedell PT, Ingle JN, Weinshilboum RM, Boughey JC, Wang L, Goetz MP, Suman V.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00012.

17.

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.

Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Jul;106(1):219-227. doi: 10.1002/cpt.1359. Epub 2019 Mar 18.

18.

The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

J Neural Transm (Vienna). 2019 Jan;126(1):35-45. doi: 10.1007/s00702-018-01966-x. Epub 2019 Jan 4.

PMID:
30610379
19.

Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.

Ahmed AT, Biernacka JM, Jenkins G, Rush AJ, Shinozaki G, Veldic M, Kung S, Bobo WV, Hall-Flavin DK, Weinshilboum RM, Wang L, Frye MA.

J Affect Disord. 2019 Mar 1;246:62-68. doi: 10.1016/j.jad.2018.12.021. Epub 2018 Dec 17.

20.

The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases.

Neavin DR, Liu D, Ray B, Weinshilboum RM.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3851. doi: 10.3390/ijms19123851. Review.

21.

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Breen G, Curtis C, Lee SH, Newhouse S, Patel H, O'Donovan M, Lewis G, Jenkins G, Weinshilboum RM, Farmer A, Aitchison KJ, Craig I, McGuffin P, Schruers K, Biernacka JM, Uher R, Lewis CM.

Eur Neuropsychopharmacol. 2018 Aug;28(8):945-954. doi: 10.1016/j.euroneuro.2018.05.009. Epub 2018 Jun 28.

PMID:
30135031
22.

Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.

Athreya AP, Gaglio AJ, Cairns J, Kalari KR, Weinshilboum RM, Wang L, Kalbarczyk ZT, Iyer RK.

IEEE Trans Nanobioscience. 2018 Jul;17(3):251-259. doi: 10.1109/TNB.2018.2851997. Epub 2018 Jul 2.

23.

Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction.

Liu D, Qin S, Ray B, Kalari KR, Wang L, Weinshilboum RM.

Drug Metab Dispos. 2018 Sep;46(9):1372-1381. doi: 10.1124/dmd.118.082164. Epub 2018 Jul 6. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):270.

24.

Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.

Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW; Mood Disorders Precision Medicine Consortium (MDPMC).

J Affect Disord. 2018 Oct 1;238:1-7. doi: 10.1016/j.jad.2018.05.005. Epub 2018 May 26.

25.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.

J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

26.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

27.

SLCO1B1 genetic variation and hormone therapy in menopausal women.

Moyer AM, de Andrade M, Faubion SS, Kapoor E, Dudenkov T, Weinshilboum RM, Miller VM.

Menopause. 2018 Aug;25(8):877-882. doi: 10.1097/GME.0000000000001109.

28.

Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM.

Biochem Pharmacol. 2018 Jun;152:279-292. doi: 10.1016/j.bcp.2018.03.032. Epub 2018 Apr 3.

29.

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.

Bidadi B, Liu D, Kalari KR, Rubner M, Hein A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM, Wang L.

Front Pharmacol. 2018 Mar 13;9:158. doi: 10.3389/fphar.2018.00158. eCollection 2018.

30.

TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence.

Ho MF, Lummertz da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, Kubo M, Wang L, Li H, Weinshilboum RM.

J Pharmacol Exp Ther. 2018 Jun;365(3):700-710. doi: 10.1124/jpet.118.247718. Epub 2018 Mar 28.

31.

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

Front Psychiatry. 2018 Mar 6;9:65. doi: 10.3389/fpsyt.2018.00065. eCollection 2018.

32.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

33.

Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure.

Orlenko A, Moore JH, Orzechowski P, Olson RS, Cairns J, Caraballo PJ, Weinshilboum RM, Wang L, Breitenstein MK.

Pac Symp Biocomput. 2018;23:460-471.

34.

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Breen G, Curtis C, Sang-Hyuk L, Newhouse S, Patel H, Guipponi M, Perroud N, Bondolfi G, O'Donovan M, Lewis G, Biernacka JM, Weinshilboum RM, Farmer A, Aitchison KJ, Craig I, McGuffin P, Uher R, Lewis CM.

Pharmacogenomics J. 2018 May 22;18(3):413-421. doi: 10.1038/tpj.2017.44. Epub 2017 Nov 21.

PMID:
29160301
35.

Pharmacogenomics: Precision Medicine and Drug Response.

Weinshilboum RM, Wang L.

Mayo Clin Proc. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. Epub 2017 Nov 1. Review.

36.

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.

Oncotarget. 2017 May 9;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

37.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.

Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M.

Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689.

38.

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L.

Clin Pharmacol Ther. 2018 Jul;104(1):201-210. doi: 10.1002/cpt.907. Epub 2017 Nov 22.

39.
40.

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM.

NPJ Breast Cancer. 2017 Aug 21;3:30. doi: 10.1038/s41523-017-0036-4. eCollection 2017.

41.

Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.

Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.

42.

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.

Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, Rübner M, Fridley BL, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L, Fasching PA, Häberle L.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):651-659. doi: 10.1055/s-0042-113189. Epub 2017 Jun 28.

43.

TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Ho MF, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, Mushiroda T, Kubo M, Wang L, Weinshilboum RM.

Mol Pharmacol. 2017 Aug;92(2):175-184. doi: 10.1124/mol.117.108340. Epub 2017 Jun 14.

44.

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.

Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM.

Breast Cancer Res Treat. 2017 Jul;164(1):189-199. doi: 10.1007/s10549-017-4243-3. Epub 2017 Apr 20.

45.

Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.

Caraballo PJ, Bielinski SJ, St Sauver JL, Weinshilboum RM.

Clin Pharmacol Ther. 2017 Aug;102(2):254-264. doi: 10.1002/cpt.707. Epub 2017 May 26. Review.

PMID:
28390138
46.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

47.

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M.

Nat Rev Drug Discov. 2017 Jan;16(1):1. doi: 10.1038/nrd.2016.234. Epub 2016 Nov 25. No abstract available.

48.

Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?

Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL.

Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25. No abstract available.

49.

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.

Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.

50.

Multidisciplinary model to implement pharmacogenomics at the point of care.

Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM.

Genet Med. 2017 Apr;19(4):421-429. doi: 10.1038/gim.2016.120. Epub 2016 Sep 22.

Supplemental Content

Loading ...
Support Center